NCT06483672View on ClinicalTrials.gov

Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Adenocarcinoma of Lung Metastatic to Brain
Interventions
DRUG

Furmonertinib

Furmonertinib 80mg, once daily, orally

DRUG

Anlotinib

Anlotinib 12mg, once daily (days 1-14, 21 days per cycle), orally

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06483672 - Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases | Biotech Hunter | Biotech Hunter